1-azabicyclo [2,2,2] octan-3-one derivatives
The present invention provides novel compounds, corresponding to formulae I and II, respectively, which are able to reactivate the apoptosis-inducing function of mutant p53 proteins. This reactivation is provided by restoration of sequence-specific DNA-binding activity and transcriptional transactivation function to mutant p53 proteins, and modulation of the conformation-dependent epitopes of the p53 protein. Accordingly, the substances according to the invention will be used in pharmaceutical compositions and methods for treatment of patients suffering from various types of tumors.
1. A pharmaceutical composition for treating a patient having cancer comprising a compound and a pharmaceutically acceptable enhancer carrier, diluent and/or excipient, wherein said compound is selected from the group consisting of 9-[2-(1-azabicyclo[2,2,2]3-oxooctyl)]-methyl-6-chloro-9H-purine, 2,2-bis(hydroxymethyl-1-azabicyclo[2,2,2]octan-3-one, and 2-hydroxymethyl-3,3-dihydroxy-1-azabicyclo[2,2,2]octane.
2. The composition according to claim 1 , wherein said compound is 2,2-bis(hydroxymethyl)-1-azabicyclo[2,2,2]octan-3-one.
3. The composition according to claim 1 , wherein said compound is 2-hydroxymethyl-3,3-dihydroxy-1-azabicyclo[2,2,2]octane.
4. The composition according to claim 1 , wherein said compound is coupled to a functional moiety.
5. The composition according to claim 1 , wherein said compound is 9-[2-(1-azabicyclo[2,2,2]3-oxooctyl)]-methyl-6-chloro-9H-purine.